Jessica Fye analyst JPMORGAN

Currently out of the existing stock ratings of Jessica Fye, 111 are a HOLD (35.35%), 171 are a BUY (54.46%), 32 are a SELL (10.19%).

Jessica Fye

Work Performance Price Targets & Ratings Chart

Analyst Jessica Fye, currently employed at JPMORGAN, carries an average stock price target met ratio of 74.28% that have a potential upside of 22.04% achieved within 136 days.

Jessica Fye’s has documented 614 price targets and ratings displayed on 49 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on DNLI, Denali Therapeutics at 04-Nov-2025.

Wall Street Analyst Jessica Fye

Analyst best performing recommendations are on STOK (STOKE THERAPEUTICS).
The best stock recommendation documented was for STOK (STOKE THERAPEUTICS) at 3/26/2024. The price target of $13 was fulfilled within 1 day with a profit of $2.71 (26.34%) receiving and performance score of 263.36.

Average potential price target upside

AMRN Amarin PLC ARNA Arena Pharmaceuticals ASND Ascendis Pharma AS BCRX BioCryst Pharmaceuticals CARA Cara Therapeutic CRNX Crinetics Pharmaceuticals DNLI Denali Therapeutics EBS Emergent Biosolutions ESPR Esperion Therapeutics HALO Halozyme Therapeutics IMGN ImmunoGen ITCI Intracellular Th JAZZ Jazz Pharmaceuticals PLC LABP Landos Biopharma MGTA Magenta Therapeutics NKTR Nektar Therapeutics STOK Stoke Therapeutics TCDA Tricida UTHR United Therapeutics IONS Ionis Pharmaceuticals KLDO Kaleido Biosciences LXRX Lexicon Pharmaceuticals RDUS Schnitzer Steel Industries APTX Aptinyx MIRM Mirum Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC LVTX LAVA Therapeutics NV ALNY Alnylam Pharmaceuticals AMAG AMAG Pharmaceuticals APRE Aprea Therapeutics AXLA Axcella Health BNTX BioNTech SE CERE Cerevel Therapeutics Holdings IMCR Immunocore Holdings Ltd INCY yte LEGN Legend Biotech Corp MDCO The Medicines Company MRNA Moderna MRSN Mersana Therapeutics NVCR Novocure Ltd RUBY Rubius Therapeutics SGEN Seagen ALKS Alkermes Plc BMRN Biomarin Pharmaceutical INSM Insmed VRTX Vertex Pharmaceuticals BGNE BeiGene Ltd RYZB RayzeBio, Common Stock ZYME Zymeworks Common Stock

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sell

$12

$-4.14 (-25.65%)

$7

5 months 17 days ago
(25-Jun-2025)

8/13 (61.54%)

$-4.19 (-25.88%)

55

Buy

1 years 5 months 24 days ago
(18-Jun-2024)

10/37 (27.03%)

$101 (102.02%)

298

Sell

2 years 22 days ago
(20-Nov-2023)

1/3 (33.33%)

$-0.8 (-0.99%)

300

Hold

$20

$3.86 (23.92%)

$60

2 years 1 months 17 days ago
(25-Oct-2023)

3/22 (13.64%)

$5.72 (40.06%)

40

Hold

$25

$8.86 (54.89%)

$40

2 years 4 months 23 days ago
(19-Jul-2023)

2/5 (40%)

$3.4 (15.74%)

215

Show more analysts

Please expand the browser size to see the chart

Which stock is Jessica Fye is most bullish on?

Potential upside of $96.39 has been obtained for VRTX (VERTEX PHARMACEUTICALS)

Which stock is Jessica Fye is most reserved on?

Potential downside of -$156 has been obtained for UTHR (UNITED THERAPEUTICS)

What Year was the first public recommendation made by Jessica Fye?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?